Lixte Biotechnology (LIXT) News Today $1.27 -0.09 (-6.61%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$1.27 0.00 (-0.01%) As of 02/21/2025 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Lixte Biotechnology Holdings IncFebruary 15, 2025 | morningstar.comLIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesFebruary 13, 2025 | globenewswire.comLixte to sell 434,784 shares at $2.415 in registered direct offeringFebruary 11, 2025 | markets.businessinsider.comLIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesFebruary 11, 2025 | globenewswire.comLixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration StatementFebruary 11, 2025 | finanznachrichten.deLixte Biotechnology requests withdrawal of registration statementFebruary 11, 2025 | markets.businessinsider.comLIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration StatementFebruary 10, 2025 | globenewswire.comMercantile Bank (NASDAQ:MBWM) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comStryve Foods (NASDAQ:SNAX) Stock Quotes, Forecast and News SummaryOctober 2, 2024 | benzinga.comLIXTE Receives U.S. Patent Issue Notification for Immune OncologySeptember 4, 2024 | globenewswire.comFirst Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma CompanyAugust 26, 2024 | finance.yahoo.comFirst Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma CompanyAugust 26, 2024 | globenewswire.comLIXTE Biotechnology Provides Update On Recent Activities and DevelopmentsAugust 19, 2024 | globenewswire.comLIXT Stock Earnings: Lixte Biotech Hldgs Reported Results for Q2 2024August 16, 2024 | investorplace.comLIXTE Biotechnology Holdings to Present at Two Investor ConferencesAugust 15, 2024 | globenewswire.comLIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical TrialJune 14, 2024 | globenewswire.comLIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical TrialJune 14, 2024 | globenewswire.comScientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune SystemJune 6, 2024 | globenewswire.comLIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical OfficerJune 3, 2024 | globenewswire.comLixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Holdings Provides Update on Recent ActivitiesMay 20, 2024 | finanznachrichten.deLIXTE Biotechnology Holdings Provides Update on Recent ActivitiesMay 20, 2024 | globenewswire.comLIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”May 8, 2024 | globenewswire.comMixed Shelf Filing Gives Micro Cap Delayed BoostApril 24, 2024 | theglobeandmail.comNEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE'S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIESMarch 29, 2024 | stockhouse.comBiotech Steals The Show Following Pre-Clinical Data AnnouncementMarch 27, 2024 | theglobeandmail.comLixte stock soars on preclinical data for lead drug LB-100March 27, 2024 | msn.comLixte Biotechnology Shares Rise 51% After Positive Data for LB-100 Cancer TreatmentMarch 27, 2024 | marketwatch.comLIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer TreatmentsMarch 21, 2024 | globenewswire.comProfessor René Bernards to Present New Pre-Clinical Data on LIXTE's LB-100 at Joint Conference of European and American Associations for Cancer ResearchFebruary 27, 2024 | globenewswire.comLIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCIFebruary 26, 2024 | globenewswire.comLixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Provides Update on Clinical Progress and Expanding CollaborationsNovember 14, 2023 | finanznachrichten.deLIXTE Biotechnology Provides Update on Clinical Progress and Expanding CollaborationsNovember 13, 2023 | finance.yahoo.comLixte Biotechnology Holdings Inc LIXTNovember 9, 2023 | morningstar.comLIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand CollaborationOctober 16, 2023 | finance.yahoo.comLIXTE Appoints Bas van der Baan as President and Chief Executive OfficerSeptember 26, 2023 | finance.yahoo.comLixte Biotechnology Holdings Inc. WtAugust 27, 2023 | wsj.comLIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq RulesJuly 20, 2023 | finance.yahoo.comWhy Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionJuly 18, 2023 | benzinga.comLIXTE Biotechnology falls after company launches $3.5M registered direct offering of sharesJuly 18, 2023 | msn.comLixte Bio Shares Tumble 31% After Pricing $3.5M Stock OfferingJuly 18, 2023 | marketwatch.comLIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq RulesJuly 18, 2023 | finance.yahoo.comLixte Biotechnology Shares Rise 25% on LB-100 Cancer Treatment ResearchJuly 17, 2023 | marketwatch.comWhat's Going On With Lixte Biotechnology (LIXT) Stock?July 17, 2023 | msn.comTrading was temporarily halted for "LIXT" at 10:07 AM with a stated reason of "LULD pause."July 17, 2023 | marketbeat.comTrading was temporarily halted for "LIXT" at 10:07 AM with a stated reason of "LULD pause."July 17, 2023 | marketbeat.comTrading was temporarily halted for "LIXT" at 10:07 AM with a stated reason of "LULD pause."July 17, 2023 | marketbeat.comTrading was temporarily halted for "LIXT" at 09:07 AM with a stated reason of "LULD pause."July 17, 2023 | marketbeat.comPreclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and ChemotherapyJuly 17, 2023 | finance.yahoo.comLIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing RequirementsJune 23, 2023 | finance.yahoo.comLIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE’s Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue SarcomasJune 7, 2023 | finance.yahoo.com Get Lixte Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter. Email Address LIXT Media Mentions By Week LIXT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LIXT News Sentiment▼0.000.60▲Average Medical News Sentiment LIXT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LIXT Articles This Week▼00▲LIXT Articles Average Week Get Lixte Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BCDA News BCTX News OMGA News ACXP News MYNZ News SNSE News TXMD News FLGC News CHRO News TLPH News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LIXT) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWatch This Robotics Demo Before March 17thJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lixte Biotechnology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lixte Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LIXT Stock Alerts